Shanghai Haohai Biological Technology (HKG:6826, SHA:688366) recorded a 1% rise in attributable profit for the year 2024 to 420.4 million yuan from 416.1 million yuan a year prior, a March 21 filing with the Hong Kong bourse said.
Earnings per share were 1.80 yuan in the year, up from 1.75 yuan in the last fiscal year.
Revenue rose by 1.7% to 2.68 billion yuan in the period from 2.63 billion yuan a year prior.
The ophthalmic products manufacturer attributed the higher profit mainly to a rise in operating revenue.
The firm proposed a final dividend of 0.60 yuan per share for the year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。